Affiliation:
1. Drug Clinical Trial Center, Peking University Third Hospital, Beijing 100191, China
Abstract
Background:
As the number of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infected
people is greatly increasing worldwide, the international medical situation becomes very serious. Potential
therapeutic drugs, vaccine and stem cell replacement methods are emerging, so it is urgent to find specific
therapeutic drugs and the best treatment regimens. After the publications on hydroxychloroquine (HCQ) with anti-
SARS-COV-2 activity in vitro, a small, non-randomized, open-label clinical trial showed that HCQ treatment was
significantly associated with reduced viral load in patients with coronavirus disease-19 (COVID-19). Meanwhile, a
large prophylaxis study of HCQ sulfate for COVID-19 has been initiated in the United States. HCQ offered a
promising efficacy in the treatment of COVID-19, but the optimal administration is still being explored.
Methods:
We used the keyword "hydroxychloroquine" to conduct a literature search in PubMed to collect relevant
literature on the mechanism of action of HCQ, its clinical efficacy and safety, pharmacokinetic characteristics,
precautions for clinical use and drug interactions to extract and organize information.
Results:
This paper reviews the mechanism, clinical efficacy and safety, pharmacokinetic characteristics, exposureresponse
relationship and precautions and drug interactions of HCQ, and summarizes dosage recommendations for
HCQ sulfate.
Conclusion:
It has been proved that HCQ, which has an established safety profile, is effective against SARS-CoV-2
with sufficient pre-clinical rationale and evidence. Data from high-quality clinical trials are urgently needed
worldwide.
Funder
Bill & Melinda Gates Foundation
13th Five-Year” National Major New Drug Projects of China, Ministry of Science and Technology of the People’s Republic of China
Publisher
Bentham Science Publishers Ltd.
Subject
Clinical Biochemistry,Pharmacology
Reference65 articles.
1. Yao X.; Cui C.; Liu D.; Li H.; Clinical pharmacological review of chloroquine against new coronavirus pneumonia. Clin Medica J 2020,18,30-33
2. Xia, J. Efficacy of Chloroquine and Lopinavir/ Ritonavir in mild/general novel coronavirus (CoVID-19) infections: a prospective, open-label, multicenter randomized controlled clinical study., 2020 11.02
3. Yao X.; Ye F.; Zhang M.; In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis; ciaa237. [Epub ahead of print]2020
4. Liu J.; Cao R.; Xu M.; Wang X.; Zhang H.; Hu H.; Li Y.; Hu Z.; Zhong W.; Wang M.; Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 2020,6,16
5. Shanghai Expert consensus on comprehensive treatment of coronavirus disease in Shanghai 2019. Chinese J Infect Diseas Shanghai Expert Group on Clinical Treatment of New Coronavirus Diseases2020,38
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献